Navigation Links
SomaLogic researchers describe revolutionary new approach to protein analysis and application to early diagnosis of lung cancer
Date:12/2/2010

Even with astounding advances in genomic science, genetic analysis of disease remains largely a measure of risk rather than actual disease state. A truer and more immediate measure of health can be obtained by analysis of proteins, especially those that are biomarkers of disease state. Until now, proteomic technologies have lacked the sensitivity, scale, and robustness to untangle the vast differences in protein types and concentration levels that underlie complex human biology and disease. In two papers published on December 2 in the open-access scientific journal PLoS One, researchers at SomaLogic, Inc., and their collaborators describe a revolutionary new approach to biomarker detection and demonstrate its potential diagnostic power in a large-scale study that identifies a panel of biomarkers that can detect lung cancer in its early and treatable stages.

Personalized medicine has to be more than prediction of risk for disease, it has to be actionable; what is the persons state of health at this moment? To determine that you have to understand what proteins are being made, and at what concentrations, even at very low levels, said Larry Gold, Founder, Chairman and CEO of SomaLogic. This has proven to be a difficult task, but we believe we have succeeded at finding a way to entirely transform protein-based diagnostics and help drive the realization of personalized medicine in this decade.

SomaLogics proteomic technology is built on two decades of painstaking work to corral aptamers short stretches of nucleic acids that form protein-binding three-dimensional structures into performing exquisitely specific recognition and binding of proteins. Through a series of chemical modifications of the nucleic acids that make up the aptamer, SomaLogic scientists were able to develop a next generation of aptamers renamed SOMAmers to reflect their increased abilities -- that together can bind proteins of widely diverse types and concentrations. And because SOMAmers are essentially small bits of DNA, current DNA measurement technologies like microarrays can be used to measure them and provide a readout of protein or biomarker types and concentrations in a fast and simple analysis. This powerful combination specific binding to individual proteins and DNA-based quantification allows the researchers to accurately detect and measure literally a thousand proteins in as little as a few drops of blood in a single experiment. The first PLoS One paper describes this breakthrough technology in detail, and demonstrates its power through application to samples from patients with chronic kidney disease, finding not only known markers of the disease but many previously unknown protein biomarkers.

Today, single protein biomarkers are the foundation of clinical diagnostics: but both normal and disease biology is far more complex than a single measurement can capture: We need to look at multiple biomarkers, or a signature of proteins, that is truly revealing about health and disease at that moment, said Steve Williams, Chief Medical Officer of SomaLogic. The SOMAmer technology empowers us for the first time to measure real biology in a clinically meaningful way.

In the second PLoS One paper, SomaLogic researchers and their collaborators at multiple sites describe the application of SOMAmers at large scale, uncovering a panel of biomarkers that announce the presence of lung cancer. Lung cancer is the leading cause of cancer deaths, mostly because it is detected under current technologies only at its latest stages. By applying SOMAmer technology to over 1300 clinical samples, the researchers rapidly identified a panel or signature of 12 proteins that together accurately reveal the presence of lung cancer in at-risk patients (e.g., long-term smokers). This finding is the basis for a new diagnostic test under development for clinical application in the next year.

By being able to detect lung cancer early, we finally have a tool to reduce the morbidity and mortality of this deadly disease with successful surgical intervention, said William Rom, Professor of Medicine and Environmental Medicine at NYU School of Medicine and a collaborator on the lung cancer study. In addition, we can avoid unnecessary treatments in patients who have a lung nodule on CT scan, but which is actually not cancer as revealed by this test.

SomaLogics scalable, flexible and robust SOMAmer-based technology is already being applied to a series of different cancers, as well as infectious, inherited, neurological and metabolic diseases that could be more effectively treated if detected early. It also holds great potential for basic research into cellular biology as well as potential therapeutic applications.


'/>"/>

Contact: Jeff Walker
jwalker@somalogic.com
303-625-9021
SomaLogic, Inc.
Source:Eurekalert

Related biology news :

1. Researchers describe first functioning lipidome of mouse macrophage
2. Researchers find link between sugar, diabetes and aggression
3. Snakes on a rope: Researchers take a unique look at the climbing abilities of boa constrictors
4. Researchers kick-start ancient DNA
5. Gene links to anorexia found by Childrens Hospital of Philadelphia researchers
6. UGA researchers identify key enzyme that regulates the early growth of breast cancer cells
7. Researchers insert identification codes into mouse embryos
8. Researchers learn that genetics determine winter vitamin D status
9. Researchers link an African lizard fossil in Africa with the Komodo dragon in Indonesia
10. FSU researchers helping K-12 teachers bring science down to Earth
11. As Arctic temperatures rise, tundra fires increase, researchers find
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC , ... announced the opening of an IoT Center of Excellence ... and expand the development of embedded iris biometric applications. ... level of convenience and security with unmatched biometric accuracy, ... identity aside from DNA. EyeLock,s platform uses video technology ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, ... launch of their brand, UP4™ Probiotics, into Target stores nationwide. The company, which ... to add Target to its list of well-respected retailers. This list includes such ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. ... test has received AOAC Research Institute approval 061601. , “This is another AOAC-RI ... stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate ...
(Date:6/23/2016)... ... , ... STACS DNA Inc., the sample tracking software company, today announced that ... joined STACS DNA as a Field Application Specialist. , “I am thrilled that ... of STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings ...
(Date:6/23/2016)... , June 23, 2016 On ... session at 4,833.32, down 0.22%; the Dow Jones Industrial Average ... 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), Aralez ... Inc. (NASDAQ: BIND ). Learn more about these ...
Breaking Biology Technology: